• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The role of CTLA-4 in the regulation of T cell immune responses.

作者信息

McCoy K D, Le Gros G

机构信息

Malaghan Institute of Medical Research, Wellington School of Medicine, New Zealand.

出版信息

Immunol Cell Biol. 1999 Feb;77(1):1-10. doi: 10.1046/j.1440-1711.1999.00795.x.

DOI:10.1046/j.1440-1711.1999.00795.x
PMID:10101680
Abstract

Over the past few years a great deal of research has examined how T cell-dependent immune responses are initiated and subsequently regulated. Ligation of the TCR with an antigenic peptide bound to an MHC protein on a professional APC provides the crucial antigen-specific stimulus required for T cell activation. Interaction of CD28 with CD80 or CD86 molecules on APC initiates a costimulatory or second signal within the T cell which augments and sustains T cell activation initiated through the TCR. However, recently it has become clear that T cell immune responses are a result of a balance between stimulatory and inhibitory signals. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is a cell surface molecule that is expressed nearly exclusively on CD4+ and CD8+ T cells. Investigation into the role of CTLA-4 in the regulation of T cell immune responses has revealed that CTLA-4 is a very important molecule involved in the maintenance of T cell homeostasis. In the present review, evidence for the proposed inhibitory role of CTLA-4 is examined and a model suggesting a role for CTLA-4 in both early and late stages of T cell activation is presented.

摘要

相似文献

1
The role of CTLA-4 in the regulation of T cell immune responses.
Immunol Cell Biol. 1999 Feb;77(1):1-10. doi: 10.1046/j.1440-1711.1999.00795.x.
2
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).使用与表面相连的抗CTLA-4(CD152)单链抗体阻断T细胞活化。
J Immunol. 2000 May 1;164(9):4433-42. doi: 10.4049/jimmunol.164.9.4433.
3
CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition.CTLA-4——不起共刺激作用的分子:通过抑制作用调节T细胞反应
Cold Spring Harb Symp Quant Biol. 1999;64:303-12. doi: 10.1101/sqb.1999.64.303.
4
The role of B7 costimulation in T-cell immunity.B7共刺激在T细胞免疫中的作用。
Immunol Cell Biol. 1999 Aug;77(4):304-11. doi: 10.1046/j.1440-1711.1999.00835.x.
5
The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.CD28/CTLA-4-B7信号通路参与了对口服花生蛋白的过敏致敏和耐受诱导过程。
J Immunol. 2007 Jun 1;178(11):6894-900. doi: 10.4049/jimmunol.178.11.6894.
6
CTLA-4 and T cell activation.细胞毒性T淋巴细胞相关抗原4与T细胞活化
Curr Opin Immunol. 1999 Jun;11(3):294-300. doi: 10.1016/s0952-7915(99)80047-8.
7
Expression and functional significance of CTLA-4, a negative regulator of T cell activation.T细胞活化负调节因子CTLA-4的表达及功能意义
Arch Immunol Ther Exp (Warsz). 2001;49(1):39-46.
8
Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo.体内短暂肽诱导的T细胞活化过程中CTLA-4和CD28表达的表型分析。
Int Immunol. 1999 May;11(5):667-75. doi: 10.1093/intimm/11.5.667.
9
Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.细胞毒性T淋巴细胞相关抗原4(CTLA-4)基因敲除小鼠的淋巴增殖性疾病的特征是Th2反应由CD28调节激活。
J Immunol. 1999 May 15;162(10):5784-91.
10
Co-stimulation in T cell responses.T细胞应答中的共刺激
Curr Opin Immunol. 1997 Jun;9(3):396-404. doi: 10.1016/s0952-7915(97)80087-8.

引用本文的文献

1
Breakthroughs in immune checkpoint therapy: overcoming NSCLC immune checkpoint therapy resistance with novel techniques.免疫检查点疗法的突破:用新技术克服非小细胞肺癌免疫检查点疗法耐药性
Front Immunol. 2025 Sep 2;16:1630940. doi: 10.3389/fimmu.2025.1630940. eCollection 2025.
2
Multilevel systems biology analysis identifies key immune response profiles and potential correlates of protection for M72/AS01E vaccine against tuberculosis.多水平系统生物学分析确定了M72/AS01E结核病疫苗的关键免疫反应特征及潜在的保护相关因素。
Clin Exp Vaccine Res. 2025 Jul;14(3):210-228. doi: 10.7774/cevr.2025.14.e21. Epub 2025 Mar 31.
3
Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy.
替雷利珠单抗与TIGIT:开创癌症免疫治疗的新时代。
Front Pharmacol. 2025 Jun 11;16:1568664. doi: 10.3389/fphar.2025.1568664. eCollection 2025.
4
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies.针对非小细胞肺癌的免疫检查点抑制剂:超越PD-1/PD-L1单克隆抗体
Cancers (Basel). 2025 Mar 6;17(5):906. doi: 10.3390/cancers17050906.
5
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.用于个性化治疗和提高疗效的革命性癌症疗法:克服免疫检查点抑制剂疗法耐药性的策略
Cancers (Basel). 2025 Mar 4;17(5):880. doi: 10.3390/cancers17050880.
6
The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects.胰腺癌的未来之路:新趋势与治疗前景
Biomedicines. 2024 Sep 2;12(9):1979. doi: 10.3390/biomedicines12091979.
7
Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?用疫苗为基础的联合疗法对抗胰腺癌:希望还是现实?
Cells. 2024 Sep 16;13(18):1558. doi: 10.3390/cells13181558.
8
Systemic lupus erythematosus therapeutic strategy: From immunotherapy to gut microbiota modulation.系统性红斑狼疮治疗策略:从免疫疗法到肠道微生物群调节。
J Biomed Res. 2024 May 25;38(6):1-16. doi: 10.7555/JBR.38.20240009.
9
Optimization of adaptation parameters from adhesion cell culture in serum-containing media to suspension in chemically defined media by superlative box design.通过最优混合设计优化从含血清培养基中的贴壁细胞培养到化学成分确定的培养基中的悬浮培养的适应参数。
Cytotechnology. 2024 Feb;76(1):39-52. doi: 10.1007/s10616-023-00596-w. Epub 2023 Sep 29.
10
Cancer stem cells in brain tumors: From origin to clinical implications.脑肿瘤中的癌症干细胞:从起源到临床意义。
MedComm (2020). 2023 Aug 9;4(4):e341. doi: 10.1002/mco2.341. eCollection 2023 Aug.